Education
About Us
Working with TipRanks
Follow Us
Humacyte (HUMA)
NASDAQ:HUMA
Earnings Data
Report Date
Mar 26, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.13Last Year’s EPS
-0.16Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted several positive developments, including a significant increase in product sales, expansion of hospital approvals, positive long-term results for Symvess, a strong financial performance with reduced net loss, successful fundraising, and expansion of intellectual property. However, challenges remain with increased administrative expenses and some resistance in the hospital VAC process due to budget constraints.Company Guidance
Significant Increase in Product Sales
Product sales improved to $703,000, a significant increase over the $100,000 reported last quarter.
Expansion of Hospital Approvals for Symvess
25 hospitals and/or health care systems have approved the purchase of Symvess, representing 92 civilian hospitals now eligible to purchase it.
Positive Long-term Results of Symvess
Studies showed high patency rates and no infections or amputations in patients treated with Symvess for vascular trauma, including in Ukraine.
Strong Financial Performance
Net loss decreased significantly to $17.5 million for the 3 months ended September 30, 2025, compared to a net loss of $39.2 million for the prior year period.
Successful Fundraising
Completed the sale of common stock and warrants that added approximately $56.5 million to the cash position.
Expansion of Intellectual Property
Granted a new U.S. patent covering the composition of a bioengineered esophagus, providing protection into 2041.
HUMA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HUMA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 12, 2025 | $1.28 | $1.25 | -2.34% |
Aug 11, 2025 | $2.48 | $1.74 | -29.84% |
May 13, 2025 | $1.32 | $1.73 | +31.06% |
Mar 28, 2025 | $2.01 | $1.96 | -2.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Humacyte (HUMA) report earnings?
Humacyte (HUMA) is schdueled to report earning on Mar 26, 2026, Before Open (Confirmed).
What is Humacyte (HUMA) earnings time?
Humacyte (HUMA) earnings time is at Mar 26, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HUMA EPS forecast?
HUMA EPS forecast for the fiscal quarter 2025 (Q4) is -0.13.